Preliminary clinical evaluation of cefmetazole dosing regimens in Japanese patients with urinary tract infections

Cefmetazole (CMZ) is widely used in Japan to treat infections such as urinary tract infections (UTIs), intra-abdominal infections, and bloodstream infections. However, pharmacokinetic and pharmacodynamic (PK/PD) data supporting the appropriate use of CMZ in Japanese patients with UTIs remain limited. Thus, as a preliminary study, we evaluated steady-state plasma concentrations of CMZ in Japanese patients with mild to moderate UTIs. Twenty-three patients with mild to moderate UTIs admitted to the Department of Urology at Gifu Prefectural General Medical Center from October 2022 to January 2023 were enrolled. Two patients were excluded due to inappropriate sampling timing and lack of steady-state samples, resulting in 21 patients included in the final analysis. Repeated doses of cefmetazole (CMZ, 1 g-per dose) were administered at various intervals (6, 8, 12, or 24 h) based on renal function. Steady-state plasma samples 2–3.25 h after infusion (near peak) as well as just before the next dose (near trough) were collected. Plasma concentrations of CMZ were measured using a validated high-performance liquid chromatography (HPLC) method. The relationship between plasma concentrations of CMZ and creatinine clearance (Ccr) was analyzed. CMZ effectively treated ESBL-E-induced UTIs in all patients (n = 5). With CMZ dosing regimens based on renal function, the mean (± SD) steady-state plasma concentrations at near-peak and near-trough were 73.8 ± 27.1 µg/mL and 14.0 ± 11.0 µg/mL, respectively. Steady-state near-peak plasma concentrations of CMZ (n = 19) were found to be negatively correlated with Ccr (R = − 0.70, p < 0.001). However, there is no correlation between Ccr and near-trough plasma concentrations of CMZ (n = 11, R = − 0.53). Preliminary clinical data suggest the potential appropriateness of the CMZ dosing regimen in patients with mild to moderate UTIs based on renal function, although further detailed population PK/PD analysis would be necessary.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Health Care and Sciences
Published
2025-12-27
DOI
https://doi.org/10.1186/s40780-025-00535-1
Primary Topic
Urinary Tract Infections Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Preliminary clinical evaluation of cefmetazole dosing regimens in Japanese patients with urinary tract infections

Tomoyuki Hirashita, Yasuhisa Oida, Kiyoyuki Kitaichi, Midori Soda et al.
Journal of Pharmaceutical Health Care and Sciences
Urinary Tract Infections Management
article

Preliminary clinical evaluation of cefmetazole dosing regimens in Japanese patients with urinary tract infections

Tomoyuki Hirashita, Yasuhisa Oida, Kiyoyuki Kitaichi, Midori Soda, Yuna Sadaka, Kotoe Inoue, Tsuyoshi Yokoi, Yuki Sasaki, Mao Tsurugaya, Kokoro Nakajima, Yoshito Takahashi
article en

Abstract

Cefmetazole (CMZ) is widely used in Japan to treat infections such as urinary tract infections (UTIs), intra-abdominal infections, and bloodstream infections. However, pharmacokinetic and pharmacodynamic (PK/PD) data supporting the appropriate use of CMZ in Japanese patients with UTIs remain limited. Thus, as a preliminary study, we evaluated steady-state plasma concentrations of CMZ in Japanese patients with mild to moderate UTIs. Twenty-three patients with mild to moderate UTIs admitted to the Department of Urology at Gifu Prefectural General Medical Center from October 2022 to January 2023 were enrolled. Two patients were excluded due to inappropriate sampling timing and lack of steady-state samples, resulting in 21 patients included in the final analysis. Repeated doses of cefmetazole (CMZ, 1 g-per dose) were administered at various intervals (6, 8, 12, or 24 h) based on renal function. Steady-state plasma samples 2–3.25 h after infusion (near peak) as well as just before the next dose (near trough) were collected. Plasma concentrations of CMZ were measured using a validated high-performance liquid chromatography (HPLC) method. The relationship between plasma concentrations of CMZ and creatinine clearance (Ccr) was analyzed. CMZ effectively treated ESBL-E-induced UTIs in all patients (n = 5). With CMZ dosing regimens based on renal function, the mean (± SD) steady-state plasma concentrations at near-peak and near-trough were 73.8 ± 27.1 µg/mL and 14.0 ± 11.0 µg/mL, respectively. Steady-state near-peak plasma concentrations of CMZ (n = 19) were found to be negatively correlated with Ccr (R = − 0.70, p < 0.001). However, there is no correlation between Ccr and near-trough plasma concentrations of CMZ (n = 11, R = − 0.53). Preliminary clinical data suggest the potential appropriateness of the CMZ dosing regimen in patients with mild to moderate UTIs based on renal function, although further detailed population PK/PD analysis would be necessary.

Journal of Pharmaceutical Health Care and SciencesVol. 12(1)
Gifu Pharmaceutical University (JP), Gifu Prefectural General Medical Center (JP)
Good health and well-being
Openalex Percentile: Top 30%
Urinary Tract Infections Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.